Testing to Rule Out Autoimmune Hepatitis
In a woman with mildly elevated ALT and alkaline phosphatase, you should first order ANA and SMA in adults, followed by serum IgG levels, and then proceed to liver biopsy if these initial tests suggest AIH. 1
Initial Serological Testing Algorithm
The 2019 AASLD guidelines provide a clear testing sequence for adults:
First-Line Autoantibody Panel
- Antinuclear antibodies (ANA) - present in 80% of AIH cases
- Smooth muscle antibodies (SMA) - present in 63% of AIH cases
- Serum IgG levels - characteristically elevated in AIH
Start with ANA and SMA testing in adults. If both are negative, then proceed to anti-LKM1 (liver kidney microsome type 1) antibodies 1. This sequential approach is more cost-effective than testing all antibodies simultaneously.
Diagnostic Accuracy Considerations
The presence of two concurrent autoantibodies (ANA + SMA) improves diagnostic accuracy from ~58% to 74% 1. Isolated ANA or SMA can occur in other liver diseases (PSC, chronic hepatitis C, NAFLD, alcoholic liver disease), but concurrent positivity of both is uncommon (<10%) outside of AIH 1.
Second-Line Serological Testing
If ANA, SMA, and anti-LKM1 are all negative but clinical suspicion remains high (seronegative AIH occurs in up to 20% of cases), order:
- Anti-SLA/LP (soluble liver antigen) - highly specific (99%) for AIH, present in 7-22% of type 1 AIH 1, 2
- Atypical pANCA - present in 50-92% of type 1 AIH but lacks specificity 1
- Anti-actin antibodies - subset of SMA, present in 86-100% of SMA-positive patients 1
Anti-SLA/LP is particularly valuable as it is the only disease-specific autoantibody and may be the sole marker in 14-20% of AIH patients 2.
Essential Exclusionary Testing
Before confirming AIH, you must exclude mimicking conditions:
- Viral hepatitis serologies: Hepatitis A, B, and C 1, 3
- Drug history: Comprehensive review of prescription and over-the-counter medications 3
- Metabolic/hereditary diseases:
- Wilson's disease (ceruloplasmin, 24-hour urinary copper)
- Hereditary hemochromatosis (iron studies, ferritin)
- Alpha-1 antitrypsin deficiency 1
Liver Biopsy - The Definitive Test
Liver biopsy is essential for diagnosis as AIH lacks a signature diagnostic marker 1. The diagnosis requires:
Histological Features Supporting AIH:
- Interface hepatitis (hallmark finding)
- Plasma cell infiltration
- Absence of bile duct injury or loss (helps exclude PBC/PSC)
- Minimal steatosis (helps exclude NAFLD) 1
The biopsy serves dual purposes: confirming AIH features and excluding alternative diagnoses or overlap syndromes 1.
Simplified Diagnostic Criteria
A validated simplified scoring system can guide diagnosis 4:
| Parameter | Points |
|---|---|
| ANA or SMA ≥1:40 | 1 point |
| ANA or SMA ≥1:80 or anti-LKM ≥1:40 or anti-SLA positive | 2 points |
| IgG >upper normal limit | 1 point |
| IgG >1.1× upper normal limit | 2 points |
| Liver histology compatible with AIH | 1 point |
| Liver histology typical of AIH | 2 points |
| Absence of viral hepatitis | 2 points |
≥6 points = probable AIH; ≥7 points = definite AIH 4
Critical Pitfalls to Avoid
Don't rely on autoantibodies alone: Up to 20% of AIH cases are seronegative 1. Clinical suspicion with compatible histology may still warrant treatment.
Don't skip the biopsy: Even with positive autoantibodies, biopsy is needed to confirm interface hepatitis and exclude overlap syndromes or alternative diagnoses 1.
Consider overlap syndromes: Test for AMA (primary biliary cholangitis) and consider imaging for PSC if cholestatic features predominate 1.
Timing matters: Autoantibody titers roughly reflect disease severity but are not established biomarkers of treatment response 1.
Special Considerations for This Patient
Given the mixed pattern (elevated ALT and alkaline phosphatase), consider: